Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM2ZGAN)

Drug Name
Mesoridazine Drug Info
Synonyms
Calodal; Lidanar; Lidanil; Mesoridazina; Mesoridazinum; Serentil; Serentil Concentrate; Thioridazien thiomethyl sulfoxide; Thioridazine monosulfoxide analog; Thioridazine thiomethyl sulfoxide; TPS 23; Tps23; Lidanar (TN); Mesoridazina [INN-Spanish]; Mesoridazinum [INN-Latin]; NC-123; Serentil (TN); TPS-23; Mesoridazine (USAN/INN); Mesoridazine [USAN:BAN:INN]; T-2-SO; THD-2-SO; Thioridazine-2-sulfoxide; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)-phenothiazine; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine; 10-(2-(1-Methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-10H-phenothiazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine; 10-[2(1-Methyl-2-piperidyl)ethyl]-2-(methylsulfinyl)phenothiazine; 10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylsulfinyl phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfinyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine
Therapeutic ClassAntipsychotic Agents
Cross-matching ID
PubChem CID
4078
ChEBI ID
CHEMBL1088
CAS Number
CAS 5588-33-0
TTD Drug ID
D04AAN
INTEDE Drug ID
DR1033

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Cell cycle 2.03 0.00e+0 110/124 (88.71%) CDC20;CCNB2;CDKN2A;...
Homologous recombination 1.79 3.43e-2 35/41 (85.37%) BARD1;RPA1;TOPBP1;...
Steroid biosynthesis 1.77 3.02e-2 19/20 (95%) SQLE;DHCR24;LBR;...
DNA replication 1.76 2.51e-2 34/36 (94.44%) FEN1;MCM5;MCM2;...
Fanconi anemia pathway 1.71 3.21e-2 36/54 (66.67%) RMI1;FANCL;RPA1;...
Platelet activation -1.64 3.85e-2 106/124 (85.48%) PIK3CD;PLCB4;COL1A1;...
Mitophagy -1.65 3.52e-2 56/68 (82.35%) NRAS;BCL2L13;MAPK8;...
Th1 and Th2 cell differentiation -1.65 3.48e-2 80/92 (86.96%) CD4;PLCG1;IL2;...
Focal adhesion -1.65 3.59e-2 180/201 (89.55%) PIK3CD;COL1A1;DIAPH1;...
Relaxin signaling pathway -1.66 3.61e-2 114/129 (88.37%) PIK3CD;PLCB4;COL1A1;...
ErbB signaling pathway -1.66 3.73e-2 79/85 (92.94%) PAK3;EGFR;BRAF;...
NOD-like receptor signaling pathway -1.66 3.86e-2 145/181 (80.11%) DNM1L;TICAM1;PLCB4;...
Viral myocarditis -1.68 3.84e-2 53/60 (88.33%) HLA-DRA;ACTB;HLA-F;...
Colorectal cancer -1.70 3.52e-2 84/86 (97.67%) FOS;BBC3;RAC3;...
Tryptophan metabolism -1.71 3.46e-2 35/42 (83.33%) GCDH;KMO;ECHS1;...
Phagosome -1.71 3.63e-2 118/152 (77.63%) DYNC1H1;SEC61G;TAP2;...
Galactose metabolism -1.72 3.31e-2 26/31 (83.87%) AKR1B10;GALT;LALBA;...
Viral protein interaction with cytokine and cytokine re... -1.73 3.14e-2 84/100 (84%) CXCL13;CSF1;PF4V1;...
Ubiquinone and other terpenoid-quinone biosynthesis -1.74 3.13e-2 9/11 (81.82%) GGCX;NQO1
Proteasome -1.75 2.83e-2 44/46 (95.65%) PSMC1;SEM1;PSMC5;...
Morphine addiction -1.76 2.69e-2 80/91 (87.91%) GABRE;GNG10;GNG7;...
Hematopoietic cell lineage -1.79 2.19e-2 90/99 (90.91%) GYPA;GP5;ANPEP;...
Bacterial invasion of epithelial cells -1.80 1.86e-2 59/77 (76.62%) GAB1;DNM1;ACTR2;...
Epithelial cell signaling in Helicobacter pylori infect... -1.81 2.02e-2 62/70 (88.57%) ATP6V0A4;MAPK8;CXCR1;...
Rheumatoid arthritis -1.82 1.76e-2 78/93 (83.87%) ATP6V0C;TNFRSF11A;HLA-DRA;...
Fructose and mannose metabolism -1.82 1.94e-2 30/33 (90.91%) PFKFB1;PMM1;HK3;...
Mineral absorption -1.85 1.61e-2 48/60 (80%) SLC39A4;TF;ATP1A2;...
Glycolysis / Gluconeogenesis -1.85 1.41e-2 56/67 (83.58%) HK3;ALDH9A1;ENO1;...
Adherens junction -1.87 9.23e-3 63/71 (88.73%) FER;SMAD4;PTPRB;...
Retinol metabolism -1.89 5.38e-3 41/68 (60.29%) DHRS9;LRAT;CYP3A4;...
Lysosome -1.95 0.00e+0 115/128 (89.84%) SGSH;HEXA;AP4S1;...
Chemokine signaling pathway -1.97 0.00e+0 163/192 (84.9%) PIK3CD;PLCB4;FGR;...
Intestinal immune network for IgA production -2.02 0.00e+0 38/48 (79.17%) HLA-DRA;IL5;CXCL12;...
Ferroptosis -2.11 0.00e+0 36/41 (87.8%) SLC3A2;TF;ALOX15;...
Asthma -2.12 0.00e+0 25/31 (80.65%) HLA-DRA;IL5;PRG2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 10uM 6H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 10uM 6H
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 10uM 6H
MDST8 CVCL_1400 Homo sapiens 10uM 6H
NCI-H508 CVCL_1561 Homo sapiens 10uM 6H
SNU-1040 CVCL_5001 Homo sapiens 10uM 6H
SNU-C4 CVCL_5008 Homo sapiens 10uM 6H
SNU-C5 CVCL_5009 Homo sapiens 10uM 6H
SW480 CVCL_0546 Homo sapiens 10uM 6H
SW620 CVCL_0547 Homo sapiens 10uM 6H
SW948 CVCL_0550 Homo sapiens 10uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 10uM 6H
HT115 CVCL_1294 Homo sapiens 10uM 6H
RKO CVCL_0504 Homo sapiens 10uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 10uM 6H
SNG-M CVCL_1707 Homo sapiens 10uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 8uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 10uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 10uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 10uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 10uM 6H
T3M-10 CVCL_1729 Homo sapiens 10uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 10uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 10uM 6H
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 10uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 10uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 10uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 10uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 10uM 6H
OV7 CVCL_1623 Homo sapiens 10uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 10uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 10uM 6H
RMUG-S CVCL_1666 Homo sapiens 10uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 10uM 6H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 10uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 10uM 6H
PL-21 CVCL_2161 Homo sapiens 10uM 6H
SKM-1 CVCL_0010 Homo sapiens 10uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 10uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 10uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 10uM 6H